pharmafileDecember 12, 2018
Tag: Pfizer , GlobalData
Pfizer’s palbociclib is the most commonly used breast cancer drug in clinical trials, according to analytics firm GlobalData.
The drug, which was used in 4% of breast cancer clinical trials conducted in 2018, was investigated for its use as a combination therapy in the vast majority of cases.
Mohamed Abukar, Pharma Analyst at GlobalData, commented: "The vast majority of trials investigating palbociclib use combination therapy (83%) to assess progression-free survival. The tubulin inhibitor paclitaxel was investigated in 3.5% of clinical trials, primarily in combination regimens; only 6.3% of clinical trials investigate the agent as monotherapy, and involved comparing different routes of administration."
Meanwhile 10.9% of all oncology trials were related to breast cancer between 1 January 2018 and 16 November 2018.
Overall, the majority of clinical trials were in Phase II (50.8%) while the US led in regards to the quantity of clinical trials they conducted with 22.4% of trials being done in United States. In comparison China, who came in second place, conducted 10.6% of clinical trials.
-----------------------------------------------------------------------
Editor's Note:
To apply for becoming a contributor of En-CPhI.cn,
welcome to send your CV and sample works to us,
Email: Julia.Zhang@ubmsinoexpo.com.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: